Jose Tallaj
Advanced Heart Failure and Transplant Cardiology · Birmingham, ALNPI 1790705978
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Paragonix Technologies, Inc. at 33.5% of the total. 2025 is the largest year on record at $689, more than ten times the $29 reported in 2019.
Across 15 payments — averaging $54.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragonix Technologies, Inc.$275
- Abiomed$271
- Abbott$161
- E.r. Squibb & Sons, L.L.C.$37
- Pfizer$35
- Scpharmaceuticals Inc.$25
- plus $18 from 2 others
Across 190 payments — averaging $3394.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$171K
- Livanova USA, Inc.$137K
- Pfizer$125K
- Array Biopharma Inc$61K
- E.r. Squibb & Sons, L.L.C.$48K
- Modernatx, Inc.$34K
- plus $68K from 4 others
What the payments were for
- Food & beverage$80298%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragonix Technologies, Inc. | 2 | $275 |
| Abiomed | 2 | $271 |
| Abbott | 2 | $161 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Pfizer | 3 | $35 |
| Scpharmaceuticals Inc. | 1 | $25 |
| Boston Scientific | 1 | $13 |
| United Therapeutics Corporation | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SherpaPak$235
- BaroGuard$235
- LUNGguard$235
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$146
How this compares
Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 116 | $2,796,790 |
| VyndamaxTafamidis | 50 | $1,086,686 |
| AdempasRiociguat | 55 | $751,276 |
| Ambrisentan | 208 | $570,311 |
| Orenitram ErTreprostinil Diolamine | 85 | $552,616 |
| LetairisAmbrisentan | 40 | $503,671 |
| OpsumitMacitentan | 27 | $343,335 |
| TracleerBosentan | 22 | $275,304 |
| AdcircaTadalafil | 52 | $209,492 |
| WinrevairSotatercept-Csrk | 12 | $175,728 |
| EntrestoSacubitril/Valsartan | 118 | $123,293 |
| CamzyosMavacamten | 13 | $104,419 |
| JardianceEmpagliflozin | 80 | $81,764 |
| Tadalafil | 107 | $75,441 |
| EliquisApixaban | 73 | $70,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $35 | $1,157,291123 claims |
| United Therapeutics CorporationAdcirca | $5 | $209,49252 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $37 | $104,41913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Birmingham
- Indranee RajapreyarBirmingham$6K
- Ayman Haj AsaadBirmingham$5K
- Heriberto Matos SantanaBirmingham$3K
- Kenneth BurnhamMobile$446K
- Kaushik JainHuntsville$80K
- David SmullDecatur$20K
- Luanda GrazetteMobile$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.